Unicycive Therapeutics: Two CRLs, One Fixable Problem
Unicycive Therapeutics Inc UNCY
$5.01
▼ -5.47%
($-0.29)
🗓️ Earnings Next Week
Open
$5.26
Prev Close
$5.30
Day Range
$4.98 – $5.29
52W Range
$3.71 – $8.74
Market Cap
$133.77M
Beta
1.72
EPS (TTM)
$-2.08
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-06-17 |
| Shares Out. | 26,700,000 |
| Website | unicycive.com/ ↗ |
| Phone | 16503840642 |
| Employees | 22 |
| Net Income | -$12.8M |
| Free Cash Flow | -$28.7M |
| Total Assets | $64.4M |
| Total Liabilities | $26.7M |
| Equity | $37.7M |
About Unicycive Therapeutics Inc
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Unicycive Therapeutics Inc is a publicly traded company under the ticker symbol UNCY on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)